BluePrint Archives

ASCO 2020: HER2 Reclassification
Gallery
ASCO 2020: HER2 Reclassification

BluePrint, Evidence, HER2-positive, Other

ASCO 2020: HER2 Reclassification

PUBLICATION: ASCO 2020 AUTHORS: Adam Brufsky, Jennifer A. Crozier, Paul Read More

kevin2024-03-26T09:33:53-07:00May 29th, 2020|BluePrint, Evidence, HER2-positive, Other|

Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test
Gallery
Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test

BluePrint, Evidence, Other, Validation

Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test

PUBLICATION: Translational Oncology Volume 13, Issue 4, April 2020, 100756 Read More

kevin2024-03-25T08:24:54-07:00April 16th, 2020|BluePrint, Evidence, Other, Validation|

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology
Gallery
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

BluePrint, Evidence, MammaPrint, Other, Validation

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue Read More

kevin2024-03-25T08:36:57-07:00September 1st, 2019|BluePrint, Evidence, MammaPrint, Other, Validation|

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study
Gallery
Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

Adjuvant, BluePrint, Evidence, MammaPrint, WSG-PRIMe

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: Read More

kevin2024-03-25T11:24:02-07:00June 1st, 2019|Adjuvant, BluePrint, Evidence, MammaPrint, WSG-PRIMe|

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis
Gallery
Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

BluePrint, Evidence, Other, Validation

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Read More

kevin2024-03-25T08:56:28-07:00March 27th, 2019|BluePrint, Evidence, Other, Validation|

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2
Gallery
BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

BluePrint, Evidence, HER2-positive, I-SPY2, Neoadjuvant, Other

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Read More

kevin2024-03-27T10:20:24-07:00April 18th, 2018|BluePrint, Evidence, HER2-positive, I-SPY2, Neoadjuvant, Other|

Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients
Gallery
Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients

BluePrint, Evidence, MammaPrint, Other, Validation

Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients

PUBLICATION: J Breast Cancer. 2017 Sep;20(3):246-253. English. Published online Sep Read More

kevin2024-03-25T09:00:19-07:00September 22nd, 2017|BluePrint, Evidence, MammaPrint, Other, Validation|

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Gallery
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

BluePrint, Evidence, NBRST, Neoadjuvant

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS: Peter Read More

kevin2024-03-25T09:14:21-07:00April 26th, 2017|BluePrint, Evidence, NBRST, Neoadjuvant|

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
Gallery
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

BluePrint, Evidence, NBRST, Neoadjuvant

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

PUBLICATION: Annals of Surgical Oncology; March 2017, Volume 24, Issue Read More

kevin2024-03-25T09:16:48-07:00October 21st, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures
Gallery
Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

BluePrint, Evidence, NBRST, Neoadjuvant

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Read More

kevin2024-03-25T09:19:31-07:00July 6th, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

ASCO 2020: HER2 Reclassification

Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

Kenyon Sweeney

Christy Garcia

PROF. LAURA VAN ‘T VEER, PhD

ROOPOM BANERJEE